Citius Pharmaceuticals Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-38174 Citius Pharmaceuticals, Inc.(Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Name of Each Exchange onWhichRegistered Common stock, $0.001 par value Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August 13, 2026, there were 27,452,570 shares of common stock, $0.001 par value, of the registrant issued and outstanding. Citius Pharmaceuticals, Inc.FORM 10-Q TABLE OF CONTENTSJune 30, 2026 PagePART I. FINANCIAL INFORMATION:1Item 1.Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets at June 30, 2026 and September 30, 20251Condensed Consolidated Statements of Operations for the Three and Nine Months Ended June 30, 2026 and20252Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months EndedJune 30, 2026 and 20253Condensed Consolidated Statements of Cash Flows for the Nine Months Ended June 30, 2026 and 20254Notes to Condensed Consolidated Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item 3.Quantitative and Qualitative Disclosures about Market Risk34Item 4.Controls and Procedures34PART II. OTHER INFORMATION35Item 1.Legal Proceedings35Item 1A.Risk Factors35Item 2.Unregistered Sales of Equity Securities and Use of Proceeds36Item 3.Defaults Upon Senior Securities36Item 4.Mine Safety Disclosures36Item 5.Other Information36Item 6.Exhibits37SIGNATURES38i EXPLANATORY NOTE In this Quarterly Report on Form 10-Q, and unless the context otherwise requires, the “Company,” “Citius Pharma,” “we,” “us,” and“our” refer to Citius Pharmaceuticals, Inc. and its wholly-owned subsidiary Leonard-Meron Biosciences, Inc., and its majority-ownedsubsidiaries, Citius Oncology, Inc. (Nasdaq: CTOR) (“Citius Oncology”) and NoveCite, Inc., taken as a whole. Mino-Lok® is our registered trademark and LYMPHIR®(denileukin diftitox) is a registered trademark of Citius Oncology. All othertrade names, trademarks and service marks appearing in this quarterly report are the property of their respective owners. We haveassumed that the reader understands that all such terms are source-indicating. Accordingly, such terms, when first mentioned in thisreport, appear with the trade name, trademark or service mark notice and then throughout the remainder of this report without tradename, trademark or service mark notices for convenience only and should not be construed as being used in a descriptive or genericsense. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements.” Forward-looking statements include, but are not limitedto, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our futureactivities or other future events or conditions. These statements are based on current expectations, estimates and projections about ourbusiness based, in part, on assumptions made by management. These statements are not guarantees of future performance and involverisks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcom